Fowler E, et al. - The risk of serious infections, such as tuberculosis (TB), increases with immunosuppressive therapies, which are effective in treating inflammatory disorders such as psoriasis. For example, patients with latent TB infection (LTBI) exhibit significantly increased risk of TB reactivation when are provided with tumour necrosis factor‐alpha inhibitors, which has led to routinely undertaking of test for TB prior to initiation of these medications. Researchers here investigated if interleukin (IL)‐17 inhibitor therapy for psoriasis also increases the risk of TB reactivation via performing a systematic review. Searching PubMed and EMBASE, 139 total articles were identified. Of these, 23 articles met the full inclusion criteria for this review. Among patients treated with IL‐17 inhibitors for psoriasis, no cases of TB reactivation was identified. This suggests the possible safety of providing IL‐17 inhibitors in psoriasis patients with LTBI who receive appropriate LTBI treatment.